/
Oncology
Prostate Carcinoma
20
Pipeline Programs↗
45
Active Trials↗
18
Companies Involved↗
Prostate Carcinoma is an emerging landscape with 20 programs across 18 companies. The most active players are Johnson & Johnson. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 27
Phase 37
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
16 of 19 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 95% of 20 pipeline programs.
Analysis
Trial Status
67
clinical trials
Recruiting30 · 45%
Completed14 · 21%
Active, not recruiting8 · 12%
Not yet recruiting5 · 7%
Terminated4 · 6%
Unknown status2 · 3%
Other4 · 6%
Clinical Trials
Trial Activity
67 trials
Outcomes After PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer: An Ambispective Multicenter Registry With a Prospective 1-10-Metastasis Cohort
Recruiting·AAffidea Nu-med Center of Oncological DIagnostics and Therapy·N/A·NCT07691697·1,000 enrolled
A Multi-Centre, Pivotal Stage, Study to Determine the Between MRI Scanner Reproducibility of Gold Standard Phantom Calibrated Acquisition Replicator (CARE) for Measurement of Apparent Diffusion Coefficients in the Prostate of Patients With MR Positive Lesions Destined for Biopsy
Recruiting·—·N/A·NCT06607783·66 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)